Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 1, 2009, Pages 79-86

  Kolesar, Jill ^a,b   Huang, Wei ^a,c   Eickhoff, Jens ^a,c   Hahn, Kristine ^a,c   Alberti, Dona ^a,c   Attia, Steven ^a,c   Schelman, William ^a,c   Holen, Kyle ^a,c   Traynor, Anne ^a,c   Ivy, Percy ^d   Wilding, George ^a,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3 Aminopyridine 2 carboxaldehyde thiosemicarbazone; Automated quantitative immunohistochemistry (AQUA); Quantitative real time PCR; Ribonucleotide reductase; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; DOXORUBICIN; IRINOTECAN; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SARCOMA; STOMACH CANCER; UTERINE CERVIX CANCER;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PROTEIN SUBUNITS; PYRIDINES; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, MESSENGER; STOMACH NEOPLASMS; THIOSEMICARBAZONES;

EID: 67349119922     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0845-0     Document Type: Article

References (25)

1. M Thelander A Gräslund L Thelander 1985 Subunit M2 of mammalian ribonucleotide reductase J Biol Chem 260 2737 2741
2. A Larsson BM Sjöberg 1986 Identification of the stable free radical tyrosine residue in ribonucleotide reductase EMBO J 5 2037 2040
3. HL Elford M Freese E Passamani HP Morris 1970 Ribonucleotide reductase and cell proliferation J Biol Chem 245 5228 5233
4. JD Heidel JY Liu Y Yen B Zhou BS Heale JJ Rossi DW Bartlett ME Davis 2007 Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo Clin Cancer Res 13 7 2207 2215 (Pubitemid 46649891)
5. TM Avolio Y Lee N Feng K Xiong H Jin M Wang A Vassilakos J Wright A Young 2007 RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo Anticancer Drugs 18 4 377 388 (Pubitemid 46712401)
6. H Fan C Villegas A Huang JA Wright 1998 The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation Cancer Res 58 1650 1653 (Bibliographic links) (Pubitemid 28215087)
7. H Fan C Villegas JA Wright 1996 Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential Proc Natl Acad Sci USA 93 14036 14040 (Pubitemid 26424241)
8. BS Zhou P Tsai R Ker J Tsai R Ho J Yu 1998 Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential Clin Exp Metastasis 16 43 49 (Pubitemid 28122554)
9. ML Kuo HS Hwang PR Sosnay KA Kunugi TJ Kinsella 2003 Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity Cancer J 9 277 285
10. A Huang H Fan WR Taylor JA Wright 1997 Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability Cancer Res 57 4876 4881 (Pubitemid 27468997)
11. BS Zhou NY Hsu BC Pan JH Doroshow Y Yen 1995 Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells Cancer Res 55 1328 1333
12. YG Goan B Zhou E Hu S Mi Y Yen 1999 Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line Cancer Res 59 4204 4207 (Pubitemid 29418726)
13. CP Jung MV Motwani GK Schwartz 2001 Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit Clin Cancer Res 7 2527 2536 (Pubitemid 32751659)
14. Schelman WR, Holen K, Mulkerin D, Kolesar J, Thomas J, Kruse M, Oliver K, Marnocha R, Eickhoff J, Wilding G (2006) ASCO Annual Meeting Proceedings part I. vol 24, No. 18S (June 20 Supplement). J Clin Oncol, p 12011
15. Chang JE, Morgan Meadows S, Traynor A, Kolesar J, Marnocha R, Lee F, Eickoff J, Beth E, Binger K, Wilding G (2006) ASCO Annual Meeting Proceedings part I. Vol 24, No. 18S (June 20 Supplement). J Clin Oncol, p 13168
16. Attia S, Kolesar J, Mahoney M, Pitot H, Laheru D, Heun J, Huang W, Antholine W, Erlichman C, Holen K (2008) A Phase 2 Consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs (in press)
17. RL Camp GG Chung DL Rimm 2002 Automated subcellular localization and quantification of protein expression in tissue microarrays Nat Med 8 11 1323 1327 (Pubitemid 35373567)
18. MA Rubin MP Zerkowski RL Camp 2004 Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements Am J Pathol 164 3 831 840 (Pubitemid 38235465)
19. Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W (2008) Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol (online 19 Sep 2008)
20. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
21. A Juhasz A Vassilakos HK Chew D Gandara Y Yen 2006 Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment Oncol Rep 15 5 1299 1304
22. JJ Knox SJ Hotte C Kollmannsberger E Winquist B Fisher EA Eisenhauer 2007 APhase II study of triapine (R) in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161) Invest New Drugs 25 5 471 477 (Pubitemid 47222906)
23. MJ Mackenzie D Saltman H Hirte J Low C Johnson G Pond 2007 Moore 2007 A phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium Invest New Drugs 25 553 558
24. Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I (2004) Lung Cancer Committee of the Hellenic Oncology Research Group. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 91(3):482-488
25. GJ Bosl WR Fair HW Herr DF Bajorin G Dalbagni AS Sarkis VE Reuter C Cordon-Cardo J Sheinfeld HI Scher 1994 Bladder cancer: advances in biology and treatment Crit Rev Oncol Hematol 16 1 33 70 (Pubitemid 24168470)